A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Active:	Yes
Cancer Type:	Esophogeal Cancer Gynecologic Cancers Lung Cancer Ovarian Cancer Prostate Cancer	NCT ID:	NCT06238479
Trial Phases:	Phase I	Protocol IDs:	LOXO-ENC-23001 (primary) NCI-2024-02612 2023-509867-26-00 J5A-OX-JZWA
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Eli Lilly and Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT06238479

Summary

The purpose of this study is to find out whether the study drug, LY4101174, is safe,
tolerable and effective in participants with advanced, or metastatic solid tumors. The
study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase
Ib (dose-expansion). The study will last up to approximately 4 years.

Objectives

This is a Phase 1a/1b multicenter, open-label study in participants with advanced or
metastatic solid tumor malignancies known to express Nectin 4. This study is comprised of
two phases: Dose Escalation and Dose Optimization (1a), and Dose expansion (1b). Phase 1a
will assess the safety, tolerability, and pharmacokinetics of LY4101174 to determine the
recommended phase 2 dose (RP2D)/optimal dose. Phase 1b will evaluate efficacy and safety
of LY4101174 at the RP2D/optimal dose in 7 expansion cohorts based on tumor type and/or
treatment history.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.